Jubilant Pharmo

Part of MojoOne Strategy

Market Cap: Mid Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE700A01033
NSEID: JUBLPHARMA
BSEID: 530019

INR

898.15

68.15 (8.21%)

BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 4.33 lacs

Click here to access the older version

{
  "main_header": {
    "sid": 525933,
    "name": "Jubilant Pharmo",
    "stock_name": "Jubilant Pharmo",
    "full_name": "Jubilant Pharmova Ltd",
    "name_url": "stocks-analysis/jubilant-pharmo",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "898.15",
    "chg": 68.15,
    "chgp": "8.21%",
    "dir": 1,
    "prev_price": "830.00",
    "mcapval": "14,305.84 Cr",
    "mcap": "Mid Cap",
    "scripcode": 530019,
    "symbol": "JUBLPHARMA",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE700A01033",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "01:29 AM",
    "bse_nse_vol": "4.33 lacs",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jubilant-pharmo-525933-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "RP",
      "url": "https://www.marketsmojo.com/mojopro/strategy/3",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jubilant-pharmo-525933-0&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Jubilant Pharmova Outperforms Sector with Strong Short-Term and Long-Term Gains",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmova-gains-5-32-amid-broader-market-decline-on-april-3-2025-1693488",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/4/JubilantPharmov_priceRelatedfactors_883378.png",
        "date": "2025-04-03 09:35:17",
        "description": "Jubilant Pharmova has experienced notable activity, outperforming its sector with a significant daily gain. The stock has shown a strong upward trend over the past week and has delivered impressive long-term returns, significantly exceeding the broader market performance over various time frames."
      },
      {
        "title": "Jubilant Pharmova Adjusts Valuation Grade, Highlighting Competitive Industry Position and Growth Potential",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmovas-valuation-grade-upgraded-from-attractive-to-very-attractive-1669837",
        "imagepath": "",
        "date": "2025-04-02 08:01:10",
        "description": "Jubilant Pharmova, a midcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment, reflecting its strong market position and financial metrics. The company currently boasts a price-to-earnings (PE) ratio of 32.84 and an EV to EBITDA ratio of 14.93, indicating a solid operational performance. Additionally, its PEG ratio stands at a notably low 0.03, suggesting favorable growth prospects relative to its valuation.\n\nIn terms of returns, Jubilant Pharmova has demonstrated impressive performance over the long term, with a 10-year return of 478.43%, significantly outpacing the Sensex's 169.02% over the same period. However, its year-to-date performance shows a decline of 18.15%, contrasting with the Sensex's modest drop of 2.71%. \n\nWhen compared to its peers, Jubilant Pharmova's valuation metrics appear more favorable, particularly against companies like Pfizer and ERIS Lifes..."
      },
      {
        "title": "Jubilant Pharmova Reports Strong Profit Growth Amid Long-Term Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jubilant-pharmova-reports-89-49-net-profit-growth-amid-declining-net-sales-1259301",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/JubilantPharmov_mojoScore_634705.png",
        "date": "2025-03-10 08:01:29",
        "description": "Jubilant Pharmova has recently experienced an evaluation adjustment following a strong financial performance in Q3 FY24-25, marked by a significant net profit increase. The company has demonstrated operational efficiency with high ROCE and turnover ratios, although it faces challenges in long-term growth trends."
      },
      {
        "title": "Jubilant Pharmova Shows Mixed Technical Trends Amidst Strong Long-Term Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmovas-technical-trend-shifts-from-mildly-bullish-to-mildly-bearish-amid-price-decline-3-1260094",
        "imagepath": "",
        "date": "2025-03-10 08:01:00",
        "description": "Jubilant Pharmova, a midcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting shifts in its technical indicators. The company's current stock price stands at 911.10, slightly down from the previous close of 912.85. Over the past year, Jubilant Pharmova has shown a notable return of 54.38%, significantly outperforming the Sensex, which recorded a mere 0.29% return in the same period.\n\nIn terms of technical metrics, the MACD indicates a bearish trend on a weekly basis while remaining bullish on a monthly scale. The Relative Strength Index (RSI) shows bullish momentum weekly, but lacks a clear signal monthly. Bollinger Bands reflect a mildly bearish stance weekly, contrasting with a bullish outlook monthly. Daily moving averages are bearish, and the KST shows a bearish trend weekly while being bullish monthly. The Dow Theory indicates a mildly bearish tren..."
      },
      {
        "title": "Jubilant Pharmova's Long-Term Growth Outpaces Market Despite Recent Fluctuations",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmova-reports-54-38-annual-gain-amid-mixed-recent-performance-trends-1236978",
        "imagepath": "",
        "date": "2025-03-07 18:00:23",
        "description": "Jubilant Pharmova, a mid-cap player in the Pharmaceuticals & Drugs industry, has shown notable activity in the stock market today. With a market capitalization of Rs 14,941.00 crore, the company has a price-to-earnings (P/E) ratio of 33.00, which is slightly below the industry average of 35.87.\n\nOver the past year, Jubilant Pharmova has outperformed the Sensex, delivering a remarkable 54.38% return compared to the Sensex's modest 0.29%. However, the stock has faced some challenges recently, with a slight decline of 0.19% today, while the Sensex dipped by just 0.01%. In the short term, the stock has gained 0.44% over the past week, although it has experienced a more significant drop of 8.70% over the past month.\n\nLonger-term performance metrics reveal a strong upward trajectory, with a 129.67% increase over the past three years and a 90.17% rise over five years. Despite recent fluctuations, Jubilant Pharmova..."
      },
      {
        "title": "Jubilant Pharmova's Stock Rebounds, Signaling Potential Market Resilience in Pharmaceuticals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmova-gains-5-83-after-six-days-of-decline-outperforming-sector-1040574",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/JubilantPharmov_priceRelatedfactors_451446.png",
        "date": "2025-02-17 10:50:13",
        "description": "Jubilant Pharmova experienced a notable stock performance on February 17, 2025, rebounding after six days of decline. The stock outperformed its sector and the broader market, reaching an intraday high and showing strength across various moving averages, indicating resilience in the pharmaceuticals sector."
      },
      {
        "title": "Jubilant Pharmova Demonstrates Resilience Amid Market Fluctuations and Sector Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmova-gains-5-47-on-february-5-2025-outperforming-sector-by-4-48-745802",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/JubilantPharmov_priceRelatedfactors_356710.png",
        "date": "2025-02-05 11:05:13",
        "description": "Jubilant Pharmova has demonstrated strong market momentum, with a notable stock increase on February 5, 2025. The company has outperformed its sector and recorded a cumulative gain over two days. Despite recent declines, its current price remains above several key moving averages, indicating resilience in a fluctuating market."
      },
      {
        "title": "Jubilant Pharmova Demonstrates Resilience Amid Market Fluctuations and Sector Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmova-gains-5-47-on-february-5-2025-outperforming-sector-by-4-48-2-745819",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/JubilantPharmov_priceRelatedfactors_356710.png",
        "date": "2025-02-05 11:05:13",
        "description": "Jubilant Pharmova has demonstrated strong market momentum, with a notable stock increase on February 5, 2025. The company has outperformed its sector and recorded a cumulative gain over two days. Despite recent declines, its current price remains above several key moving averages, indicating resilience in a fluctuating market."
      },
      {
        "title": "Jubilant Pharmova Reports Strong Q3 Growth and Improved Operational Efficiency",
        "link": "https://www.marketsmojo.com/news/result-analysis/jubilant-pharmova-reports-115-increase-in-profit-before-tax-for-q3-fy24-25-563149",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/1/JubilantPharmov_quaterlyResult_316727.png",
        "date": "2025-01-31 15:32:12",
        "description": "Jubilant Pharmova has reported strong financial results for the quarter ending December 2024, with significant year-on-year growth in Profit Before Tax and Profit After Tax. The company also showcased improved operational efficiency, strong inventory and debt management, and enhanced liquidity, reflected in its cash reserves and low Debt-Equity Ratio."
      }
    ],
    "total": 108,
    "sid": "525933",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/jubilant-pharmova-525933"
  },
  "announcements": [
    {
      "caption": "Amended And Restated Deed Of Private Trust Dated March 25 2025",
      "datetime": "25-Mar-2025",
      "details": "Amended and Restated Deed of Private Trust dated March 25 2025",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "24-Mar-2025",
      "details": "Intimation for closure of Trading Window",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Jubilant Biosys Innovative Research Services Pte Limited Singapore Has Executed Shareholders Agreement And Other Transition Agreements With Pie",
      "datetime": "20-Mar-2025",
      "details": "Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 - Jubilant Biosys Innovative Research Services Pte Limited Sinagpore has executed Shareholders Agreement and other transition agreements with Pierre Fabre SA.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jubilant Pharmova Ltd has declared <strong>500%</strong> dividend, ex-date: 02 Aug 24",
          "dt": "2024-08-02",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Jubilant Pharmova Ltd has announced <strong>1:5</strong> stock split, ex-date: 17 Mar 06",
          "dt": "2006-03-17",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Jubilant Pharmova Outperforms Sector with Strong Short-Term and Long-Term Gains

2025-04-03 09:35:17

Jubilant Pharmova has experienced notable activity, outperforming its sector with a significant daily gain. The stock has shown a strong upward trend over the past week and has delivered impressive long-term returns, significantly exceeding the broader market performance over various time frames.

Jubilant Pharmova Adjusts Valuation Grade, Highlighting Competitive Industry Position and Growth Potential

2025-04-02 08:01:10

Jubilant Pharmova, a midcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment, reflecting its strong market position and financial metrics. The company currently boasts a price-to-earnings (PE) ratio of 32.84 and an EV to EBITDA ratio of 14.93, indicating a solid operational performance. Additionally, its PEG ratio stands at a notably low 0.03, suggesting favorable growth prospects relative to its valuation. In terms of returns, Jubilant Pharmova has demonstrated impressive performance over the long term, with a 10-year return of 478.43%, significantly outpacing the Sensex's 169.02% over the same period. However, its year-to-date performance shows a decline of 18.15%, contrasting with the Sensex's modest drop of 2.71%. When compared to its peers, Jubilant Pharmova's valuation metrics appear more favorable, particularly against companies like Pfizer and ERIS Lifes...

Jubilant Pharmova Reports Strong Profit Growth Amid Long-Term Challenges

2025-03-10 08:01:29

Jubilant Pharmova has recently experienced an evaluation adjustment following a strong financial performance in Q3 FY24-25, marked by a significant net profit increase. The company has demonstrated operational efficiency with high ROCE and turnover ratios, although it faces challenges in long-term growth trends.

Jubilant Pharmova Shows Mixed Technical Trends Amidst Strong Long-Term Performance

2025-03-10 08:01:00

Jubilant Pharmova, a midcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting shifts in its technical indicators. The company's current stock price stands at 911.10, slightly down from the previous close of 912.85. Over the past year, Jubilant Pharmova has shown a notable return of 54.38%, significantly outperforming the Sensex, which recorded a mere 0.29% return in the same period. In terms of technical metrics, the MACD indicates a bearish trend on a weekly basis while remaining bullish on a monthly scale. The Relative Strength Index (RSI) shows bullish momentum weekly, but lacks a clear signal monthly. Bollinger Bands reflect a mildly bearish stance weekly, contrasting with a bullish outlook monthly. Daily moving averages are bearish, and the KST shows a bearish trend weekly while being bullish monthly. The Dow Theory indicates a mildly bearish tren...

Jubilant Pharmova's Long-Term Growth Outpaces Market Despite Recent Fluctuations

2025-03-07 18:00:23

Jubilant Pharmova, a mid-cap player in the Pharmaceuticals & Drugs industry, has shown notable activity in the stock market today. With a market capitalization of Rs 14,941.00 crore, the company has a price-to-earnings (P/E) ratio of 33.00, which is slightly below the industry average of 35.87. Over the past year, Jubilant Pharmova has outperformed the Sensex, delivering a remarkable 54.38% return compared to the Sensex's modest 0.29%. However, the stock has faced some challenges recently, with a slight decline of 0.19% today, while the Sensex dipped by just 0.01%. In the short term, the stock has gained 0.44% over the past week, although it has experienced a more significant drop of 8.70% over the past month. Longer-term performance metrics reveal a strong upward trajectory, with a 129.67% increase over the past three years and a 90.17% rise over five years. Despite recent fluctuations, Jubilant Pharmova...

Jubilant Pharmova's Stock Rebounds, Signaling Potential Market Resilience in Pharmaceuticals

2025-02-17 10:50:13

Jubilant Pharmova experienced a notable stock performance on February 17, 2025, rebounding after six days of decline. The stock outperformed its sector and the broader market, reaching an intraday high and showing strength across various moving averages, indicating resilience in the pharmaceuticals sector.

Jubilant Pharmova Demonstrates Resilience Amid Market Fluctuations and Sector Performance

2025-02-05 11:05:13

Jubilant Pharmova has demonstrated strong market momentum, with a notable stock increase on February 5, 2025. The company has outperformed its sector and recorded a cumulative gain over two days. Despite recent declines, its current price remains above several key moving averages, indicating resilience in a fluctuating market.

Jubilant Pharmova Demonstrates Resilience Amid Market Fluctuations and Sector Performance

2025-02-05 11:05:13

Jubilant Pharmova Reports Strong Q3 Growth and Improved Operational Efficiency

2025-01-31 15:32:12

Jubilant Pharmova has reported strong financial results for the quarter ending December 2024, with significant year-on-year growth in Profit Before Tax and Profit After Tax. The company also showcased improved operational efficiency, strong inventory and debt management, and enhanced liquidity, reflected in its cash reserves and low Debt-Equity Ratio.

View All News

Announcement

Amended And Restated Deed Of Private Trust Dated March 25 2025

25-Mar-2025 | Source : BSE

Amended and Restated Deed of Private Trust dated March 25 2025

Closure of Trading Window

24-Mar-2025 | Source : BSE

Intimation for closure of Trading Window

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Jubilant Biosys Innovative Research Services Pte Limited Singapore Has Executed Shareholders Agreement And Other Transition Agreements With Pie

20-Mar-2025 | Source : BSE

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 - Jubilant Biosys Innovative Research Services Pte Limited Sinagpore has executed Shareholders Agreement and other transition agreements with Pierre Fabre SA.